Moolec Science (MLEC) Achieves Major Milestone with 45% GLA Concentration in Commercial-Scale Safflower Production

Moolec Science Limited (NASDAQ: MLEC), a wholly-owned subsidiary of Moolec Science SA (NASDAQ:MLEC), announced breakthrough results from its U.S. GLASO1 safflower platform, confirming gamma-linolenic acid (GLA) concentrations of approximately 45% following commercial-scale crushing operations.

The innovation-driven molecular farming company, which engineers plants and microbes to unlock scalable protein solutions for the global food industry, described the achievement as a critical validation of its technology’s commercial viability within existing agricultural infrastructure.

Commercial-Scale Validation Confirms Platform Performance

Following harvest, safflower produced under the GLASO1 program underwent processing through standard U.S. crushing operations. The results demonstrated both high GLA concentration and full compatibility with existing agricultural and industrial infrastructure – two essential requirements for commercial scalability.

The approximately 45% GLA concentration positions the GLASO1 platform among the highest-performing GLA-producing systems reported at commercial scale, according to the company.

2025 Campaign Delivers Strong Year-Over-Year Growth

Moolec’s 2025 U.S. safflower campaign represented the company’s first successful transition from development-stage operations to full commercial agricultural execution:

• 1,100 acres of engineered safflower cultivated across the United States
• Average yield of approximately 2,200 lbs/acre
• 57% year-over-year yield increase from ~1,400 lbs/acre in 2024
• Harvest performance materially exceeded internal forecasts

The campaign marked a significant expansion from prior smaller-scale deployments, demonstrating the platform’s ability to perform at commercial volumes.

Strategic Market Positioning

The high GLA concentration achieved through molecular farming technology strengthens Moolec’s positioning in the U.S. nutrition and dietary supplements market, where demand increasingly favors high-concentration functional lipids, plant-engineered traceable ingredients, and production systems that integrate with existing infrastructure.

Early engagement with U.S.-based market participants supports the company’s execution-led growth strategy, which emphasizes validated performance over speculative scale-up.

Management Commentary

“The U.S. GLASO1 platform has reached an inflection point,” said Alejandro Antalich, CEO of Moolec Science. “Achieving approximately 45% GLA concentration at commercial scale confirms that our technology is not only scientifically differentiated, but operationally executable within existing U.S. agricultural and processing infrastructure.”

Antalich emphasized the collaborative nature of the achievement: “This reflects disciplined execution and close collaboration with best-in-class U.S. operators across the agricultural and processing value chain. Together, we have successfully validated acreage expansion, harvest performance, and crushing operations at scale. Our focus now is to build on this foundation through disciplined growth and the conversion of this operational advantage into sustainable, recurring revenue.”

Next Steps

With commercial-scale validation now confirmed across cultivation, harvest, and crushing operations, Moolec is positioned to advance toward revenue generation from its GLASO1 platform while maintaining its disciplined approach to agricultural expansion and market development.

About Moolec Science

Moolec Science SA (NASDAQ:MLEC) is an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food industry through its molecular farming platform.

For more on fintech catalysts, see our recent analysis of the OLB Group PayPal deal.